College Stock: Penny Stock News

$IVOB just released news about the results of a 50 patient study, which were recently presented at the annual Salvador Society of Endoscopy and Reproduction Symposium dedicated to the INVO technology.

The press release tells the world that the study had a 36% clinical pregnancy rate, which is equivalent to conventional IVF procedures currently in use.

The Dean believes this is big news for The Dean’s Billion Dollar Baby because it not only shows that the INVO procedure is just as effective as common, approved IVF procedures but also shows that $IVOB‘s infertility treatment is consistent.

The Dean wants all of his students to take a quick look at this press release from late October, which describes the results of a 28 patient study with a 36% ongoing pregnancy rate. What’s even better about today’s $IVOB news is that the INVO procedure proved to be just as effective in a study with twice as many patients.

Additionally, the results of $IVOB‘s most recent study showed a multiple pregnancy rate of only 6%, which is significantly lower than the multiple pregnancy rate of traditional IVF procedures. The Dean believes this also reaffirms $IVOB as a safe, cost-effective infertility treatment, which could become extremely appealing to more than 150 million infertile couples in countries around the world.

But wait there’s more. At the conference, IVF pioneer, Dr. Rene Frydman, who’s credited with the first IVF birth in France and the second in the entire European continent, presented on mild ovarian stimulation—the very same method which has successfully been used in the INVO procedure time and time again.

The Dean likes the fact that more than 100 physicians from all over Central and South America attended the conference to learn and celebrate $IVOB‘s effectiveness and appeal, and the full details of the study will be published in a peer review journal for even more qualified decision makers in the scientific and medical worlds to see.

Also, The Dean wants all of his students to know that $IVOB is in fact Ivy League—and this includes the management team. Confirmation of this is the fact the $IVOB CEO Katie Karloff addressed the concerns and inquiries of shareholders by telling the investment world that, since they’ve been public, the company has only sold 30,000 (or .09%) of their 31.3 million shares.

Furthermore, $IVOB management believes in the long-term value of their stock and have sacrificed for the future of the company by not receiving salaries in the past year.

The Dean sees all of these developments as large footsteps along the path of $IVOB becoming The Dean’s Billion Dollar Baby.